- Home
- DNLI vs NAMS Comparison
DNLI vs NAMS Comparison
Compare DNLI & NAMS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DNLI
- NAMS
- Stock Information
- Founded
- DNLI 2013
- NAMS 2019
- Country
- DNLI United States
- NAMS Netherlands
- Employees
- DNLI N/A
- NAMS N/A
- Industry
- DNLI Biotechnology: Biological Products (No Diagnostic Substances)
- NAMS Biotechnology: Pharmaceutical Preparations
- Sector
- DNLI Health Care
- NAMS Health Care
- Exchange
- DNLI Nasdaq
- NAMS Nasdaq
- Market Cap
- DNLI 2.1B
- NAMS 2.5B
- IPO Year
- DNLI 2017
- NAMS N/A
- Fundamental
- Price
- DNLI $13.98
- NAMS $23.23
- Analyst Decision
- DNLI Strong Buy
- NAMS Strong Buy
- Analyst Count
- DNLI 15
- NAMS 9
- Target Price
- DNLI $33.85
- NAMS $41.11
- AVG Volume (30 Days)
- DNLI 1.5M
- NAMS 858.2K
- Earning Date
- DNLI 08-04-2025
- NAMS 08-06-2025
- Dividend Yield
- DNLI N/A
- NAMS N/A
- EPS Growth
- DNLI N/A
- NAMS N/A
- EPS
- DNLI N/A
- NAMS N/A
- Revenue
- DNLI N/A
- NAMS $47,140,000.00
- Revenue This Year
- DNLI N/A
- NAMS N/A
- Revenue Next Year
- DNLI $323.34
- NAMS N/A
- P/E Ratio
- DNLI N/A
- NAMS N/A
- Revenue Growth
- DNLI N/A
- NAMS 586.97
- 52 Week Low
- DNLI $10.57
- NAMS $14.06
- 52 Week High
- DNLI $33.33
- NAMS $27.29
- Technical
- Relative Strength Index (RSI)
- DNLI 45.66
- NAMS 63.86
- Support Level
- DNLI $13.70
- NAMS $22.00
- Resistance Level
- DNLI $14.60
- NAMS $24.82
- Average True Range (ATR)
- DNLI 0.65
- NAMS 1.19
- MACD
- DNLI -0.06
- NAMS 0.22
- Stochastic Oscillator
- DNLI 13.13
- NAMS 69.49
About DNLI Denali Therapeutics Inc.
Denali Therapeutics Inc is a biotechnology company that is engaged in developing and discovering therapeutics to defeat neurodegeneration disease. The company's development programs include the LRRK2 Inhibitor Program, which develops brain penetrant small molecule LRRK2 inhibitor product candidates for Parkinson's disease. Its key products include DNL201, DNL151, DNL747, ATV (Antibody Transport Vehicle), ETV (Enzyme Transport Vehicle), and others.
About NAMS NewAmsterdam Pharma Company N.V.
NewAmsterdam Pharma Co NV is a late-stage biopharmaceutical company with a mission to improve patient care in populations with metabolic diseases where currently approved therapies have not been adequate or well tolerated. Its product, obicetrapib, is a next-generation, oral, low-dose CETP inhibitor that is developed to potentially overcome the limitations of current LDL-C lowering treatments.